Royalty Pharma stock
RPRXNASDAQRoyalty Pharma plc, HealthcareISIN GB00BMVP7Y09
71Score 71 out of 100, Strong
Price and trend
83 / 100
Price history
+74% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 27% above it.
Since February 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 75).
The price is 1.5% below its 52-week high. Largest decline in 6 years: 54% (January 2021 to December 2024).
Chart figures for advanced users
- SMA 50$61.41
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$54.48
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$38.09
- The lowest closing price of the last twelve months.
- Resistance$70.01
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Royalty Pharma plc belongs to the Medical (Pharmaceuticals) industry (United States) and, with a market value of $30.71B, is the largest of 15 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.38B (up 5.1% year on year) and earnings of $770.95M (down 10.2%).
- MEQIRI Score 71 out of 100 (Strong): rank 118 of 702 in Healthcare, median 53.
Show more
- The P/E is 57.2 (Medical (Pharmaceuticals) median 35.7, own median of recent years 16.6).
- Our model puts fair value at $80.04, with the price 14% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 440% of earnings over the last 12 months.Fundamentals 84
- High marginNet margin 25.7% over the last 12 months, Medical (Pharmaceuticals) median 8.7%.Profitability 73
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 84
Weaknesses
- Richly valuedP/E 57.2, Medical (Pharmaceuticals) median 35.7, own median 16.6.Valuation 34
- DilutionShare count up 11% since 2020.
Its standout strengths are momentum and fundamentals, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- price up very strongly over the past year
What lowers it
- solid fundamentals
- calm price action
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $57.17 and expensive above $133.39 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $116.99 (cash-flow model) and $43.08 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $70.82, at 8.2% it would be $93.49.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (35.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 11.4% on the twelve months before. Revenue has grown solidly since 2015, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating 66%, net 32%. Last 12 months: net 26%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 10 Feb 2027in 89 days
- Last reported
- 4 Nov 2026EPS reported $1.21 (expected $1.18)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $5.39+1.3%
- Revenue
- $3.54B+1.0%
- Earnings per share
- $5.91+1.9%
- Revenue
- $3.86B+1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −0.4%2026 guidance raised for the second consecutive quarter: portfolio receipts $3.4 billion to $3.5 billion, up from $3.325 billion to $3.45 billion.
“We now expect portfolio receipts to be in the range of $3.4 billion to $3.5 billion up from $3.325 billion to $3.45 billion previously.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $34.57M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Urist MarshallSale
5 Oct 2026, EVP, Research & Investments
- Shares
- 4,126
- Price
- $57.10
- Value
- $235,595
- Urist MarshallSale
28 Sept 2026, EVP, Research & Investments
- Shares
- 4,126
- Price
- $57.88
- Value
- $238,813
- Hite ChristopherSale
22 Sept 2026, EVP & Chairman, Partnering
- Shares
- 100,000
- Price
- $58.53
- Value
- $5.85M
Show 10 more
- Hite ChristopherSale
18 Aug 2026, EVP & Chairman, Partnering
- Shares
- 100,000
- Price
- $59.97
- Value
- $6M
- Coyne Terrance P.Sale
13 Aug 2026, EVP & CFO
- Shares
- 11,002
- Price
- $58.68
- Value
- $645,551
- Urist MarshallSale
1 Jul 2026, EVP, Research & Investments
- Shares
- 9,099
- Price
- $55.88
- Value
- $508,454
- Hite ChristopherSale
30 Jun 2026, EVP & Chairman, Partnering
- Shares
- 130,000
- Price
- $56.50
- Value
- $7.35M
- Urist MarshallSale
24 Jun 2026, EVP, Research & Investments
- Shares
- 9,098
- Price
- $55.18
- Value
- $502,067
- Hite ChristopherSale
23 Jun 2026, EVP & Chairman, Partnering
- Shares
- 150,000
- Price
- $54.40
- Value
- $8.16M
- Coyne Terrance P.Sale
26 May 2026, EVP & CFO
- Shares
- 64,399
- Price
- $53.98
- Value
- $3.48M
- Urist MarshallSale
20 May 2026, EVP, Research & Investments
- Shares
- 13,684
- Price
- $52.75
- Value
- $721,838
- Urist MarshallSale
14 May 2026, EVP, Research & Investments
- Shares
- 13,684
- Price
- $53.06
- Value
- $726,137
- Norden GregorySale
14 May 2026, Board
- Shares
- 3,045
- Price
- $53.00
- Value
- $161,385
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Royalty Pharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 71
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next smaller companies by market value
- Swedish Orphan BiovitrumSOBI.ST $16.99B75
- JD Health International6618.HK $16.65B70
- Sino Biopharmaceutical1177.HK $12.58B65
- Recordati Industria Chimica e FarmaceuticaREC.MI $11.92B74
- Kyowa Kirin4151.T $8.4B77
- Corcept TherapeuticsCORT $8.07B75
- Kiniksa Pharmaceuticals InternationalKNSA $7.56B68
- Tsuruha Holdings3391.T $7.1B62
ETFs that hold Royalty Pharma
Held by 117 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.61% | 0.49% | €26.29M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.97% | 0.35% | €1.25B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 1.58% | 0.25% | €45.16M |
Show 5 more
| Amundi MSCI World SRI Climate Paris Aligned UCITS ETF Acc EUR HedgedMWSH | 0.75% | 0.20% | €4.07B |
| UBS Factor MSCI USA Low Volatility UCITS ETF hEUR accUBUV | 0.75% | 0.21% | €65.24M |
| Fidelity US Quality Income UCITS ETF EUR Hedged AccFUSU | 0.73% | 0.30% | €2.1B |
| Amundi MSCI World Climate Paris Aligned UCITS ETF AccPABW | 0.62% | 0.20% | €1.33B |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 0.53% | 0.18% | €839.61M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.